ArticleOncology letters2022

Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer.

Xinlei Hou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.